Eurobio Scientific finalise l'acquisition de l'unité Sciences de la vie de Voden Medical Instruments Spa en Italie ...

VigRX Plus is the result of collaboration between herbal scientists, medical consultants, and nutraceutical engineers.

Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy En cliquant sur ce lien, vous acceptez l'utilisation de cookies sur ce site internet.

Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic ...

Direct Meds LLC, a fast-scaling telemedicine provider serving the U.S. and Canada, today announced a company-wide deployment of artificial intelligence (AI) technologies to ensure scalable, efficient ...

PCS11T: PCS11T is Processa’s preclinical oncology asset based on the active metabolite of irinotecan. The company continues to define and explore preclinical and clinical development strategies as ...

The Company notes that the Dogecoin Protocol remains under development, and there can be no assurance regarding its completion, features, or timing of deployment.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC ...

The Digital Health Awards celebrates the best digital health resources developed for consumers and healthcare professionals. Visory Health was recognized as a digital resource that is redefining ...

The groundbreaking study delivers unprecedented insight into how AI influences the reputation of the 50 most prominent OTC brands across ten major product categories. CeraVe came out as the leading ...

CHICAGO, July 01, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for ...

In addition, the Company has granted the underwriter a 45-day option to purchase up to 180,000 additional shares of common stock and/or 180,000 Common Warrants, solely to cover over-allotments, if any ...